Tanezumab Biosimilar, Human NGF Monoclonal Antibody

Tanezumab is a humanized IgG2-kappa monoclonal antibody against nerve growth factor (NGF) as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. Tanezumab selectively targets, binds to, and inhibits NGF. Tanezumab acts in the periphery in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse or dependence. Tanezumab biosimilar uses the same protein sequences as the therapeutic antibody tanezumab.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG2 kappa
Class	Monoclonal
Type	Antibody
Immunogen	Human nerve growth factor (NGF) protein
Clone	Tanezumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	145.44 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4